A CHEK2 mutation is an inherited change in the CHEK2 gene that increases a person’s risk of developing certain cancers, most notably breast cancer. It falls into the category of “moderate-penetrance” cancer genes, meaning it raises risk meaningfully but not as dramatically as better-known genes like BRCA1 or BRCA2. Women who carry a CHEK2 mutation face roughly two to three times the average risk of breast cancer, with lifetime estimates generally ranging from 20% to 33% depending on family history.
If you’ve received this result from genetic testing, here’s what it means, how it affects cancer risk, and what screening typically looks like going forward.
What the CHEK2 Gene Does
The CHEK2 gene provides instructions for making a protein called CHK2, which acts as a checkpoint in your cells’ damage-repair system. When your DNA sustains a break (something that happens routinely from normal cell activity, UV exposure, or other stressors), CHK2 helps coordinate the response. It activates BRCA1 and BRCA2 proteins to carry out precise repairs, pauses the cell cycle so the damage can be fixed before the cell divides, and stabilizes a key tumor-suppressing protein called p53. If the damage is too severe to fix, CHK2 can trigger the cell to self-destruct rather than pass along errors.
When CHEK2 is mutated, this repair system becomes less reliable. The cell is forced to rely on messier, error-prone backup repair methods. Those backup methods are more likely to introduce new mutations with each repair attempt, which over time raises the odds that a cell accumulates enough damage to become cancerous. In short, CHEK2 normally functions as a tumor suppressor, and losing that function removes one layer of protection.
Types of CHEK2 Mutations
Not all CHEK2 mutations carry the same level of risk. They generally fall into two categories:
- Protein-truncating variants cut the protein short so it can’t function at all. The most well-studied of these is called 1100delC, a frameshift mutation found most commonly in people of Northern and Western European descent. It occurs in roughly 0.7% of those populations.
- Missense variants swap a single building block in the protein, which may partially impair its function rather than eliminating it entirely. The most studied missense variant is called I157T.
In a large catalog of CHEK2 mutations, about 100 are missense changes, 17 are frameshift mutations, and 9 are nonsense mutations (which also truncate the protein). For breast cancer, the truncating variants like 1100delC tend to confer a higher risk. For other cancers the picture is more complex. In one study of colorectal cancer risk, the I157T missense variant was associated with a 1.5-fold increased risk, while the truncating mutations showed no clear increase at all.
If your genetic test result mentions a “variant of uncertain significance” (VUS), that means the specific change in your CHEK2 gene hasn’t been studied enough to confirm whether it raises cancer risk. These results are common and can sometimes be reclassified over time as more data becomes available.
Breast Cancer Risk for Women
Breast cancer is the most clearly established risk tied to CHEK2 mutations, and the numbers depend heavily on family history. For women who carry a protein-truncating variant and have no family history of breast cancer, the lifetime risk is around 20%. For those with a first-degree relative (mother, sister, or daughter) who has had breast cancer, that number climbs to about 34%. One study of women with a family history estimated cumulative risk at 37% by age 70.
A large population-based study in Australia tracked how that risk builds over a lifetime: roughly 2.6% by age 40, rising to 33% by age 80. The risk remains significant even later in life. Women aged 66 to 85 who carry the mutation still face a remaining lifetime risk of about 15%.
To put this in perspective, the average woman’s lifetime breast cancer risk is about 13%. A CHEK2 carrier’s risk is elevated enough to qualify for enhanced screening but generally lower than the 45% to 70% lifetime risk associated with BRCA1 or BRCA2 mutations.
Prostate Cancer and Other Risks
For men, the most relevant association is with prostate cancer. CHEK2 mutations roughly double the risk compared to the general population, where the baseline lifetime risk is already around 12%. A meta-analysis found that the 1100delC truncating variant was associated with a 3.3-fold increased risk, while the I157T missense variant carried about a 1.8-fold increase.
Beyond breast and prostate cancer, several other cancer types have been linked to CHEK2, including colorectal, kidney, thyroid, pancreatic, stomach, and bladder cancers, as well as melanoma and certain blood cancers. However, the evidence for most of these remains inconsistent. Studies on colorectal cancer risk have produced conflicting results, and there is not currently enough data to support specific screening changes based on CHEK2 status alone. The same applies to kidney cancer: most studies lean toward a possible increased risk, but the association hasn’t been confirmed strongly enough to drive formal recommendations.
How CHEK2 Is Inherited
CHEK2 mutations follow an autosomal dominant inheritance pattern, meaning you only need one copy of the altered gene (inherited from one parent) for your cancer risk to be elevated. If one of your parents carries the mutation, you have a 50% chance of inheriting it. Each of your siblings has the same 50% odds independently.
This is why genetic counselors typically recommend that close family members consider testing once a CHEK2 mutation is identified in a family. Knowing who carries the variant allows those individuals to start enhanced screening and make more informed decisions about their health.
What Screening Looks Like
Because CHEK2 carrier status pushes lifetime breast cancer risk above the 20% threshold used by most guidelines, women with a confirmed pathogenic variant generally qualify for enhanced breast cancer screening. This typically means annual breast MRI in addition to mammography, often starting earlier than the standard age of 40. The exact schedule depends on your specific variant, family history, and the overall risk calculation your provider puts together.
For prostate cancer, men who carry a CHEK2 mutation may benefit from earlier or more frequent screening with PSA testing, though guidelines vary. The doubled risk on top of an already common cancer makes this a conversation worth having with a provider, especially for men with a family history of prostate cancer.
For colorectal cancer, no CHEK2-specific screening schedule exists. The American Cancer Society recommends average-risk adults begin colonoscopy screening at age 45 and repeat every 10 years. People with a genetic predisposition syndrome may need to start earlier and screen more frequently, but current evidence has not established CHEK2 as a clear enough colorectal cancer risk to change those standard timelines.
CHEK2 Compared to BRCA Mutations
People who learn they carry a CHEK2 mutation often wonder how it compares to BRCA1 or BRCA2. The key difference is penetrance, meaning the likelihood that carrying the mutation will actually result in cancer. BRCA mutations are high-penetrance: they carry lifetime breast cancer risks of 45% to 72%, and they significantly increase ovarian cancer risk as well. CHEK2 is moderate-penetrance, with lower overall risk and no established link to ovarian cancer.
This distinction matters for management decisions. Risk-reducing mastectomy, which is commonly discussed for BRCA carriers, is not typically recommended for CHEK2 carriers, though individual circumstances and family history can shift that calculus. Enhanced surveillance with imaging is the more standard approach. CHEK2 mutations also interact with the BRCA repair pathway (since CHK2 helps activate BRCA proteins), which has implications for treatment options if cancer does develop.
Having a CHEK2 mutation is not a cancer diagnosis. Many carriers live their entire lives without developing cancer. What the mutation does is provide information that lets you and your healthcare team make smarter decisions about when and how to screen, catching problems earlier when they’re most treatable.